| Literature DB >> 34944471 |
Arzoo Pannu1, Prabodh Chander Sharma2, Vijay Kumar Thakur3,4, Ramesh K Goyal1.
Abstract
Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant.Entities:
Keywords: anti-depressants; anti-oxidant; depression; flavonoids; nutraceuticals
Mesh:
Substances:
Year: 2021 PMID: 34944471 PMCID: PMC8698856 DOI: 10.3390/biom11121825
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Skeleton of Flavonoids.
Figure 2Skeleton of Flavones.
Flavones and their Structure activity relationship.
| Sr. No. | Flavones | C5 | C6 | C7 | C8 | C3′ | C4′ |
|---|---|---|---|---|---|---|---|
| 1. | 7,8-Dihydroxyflavone | -OH | -OH | ||||
| 2. | Amentoflavone | -OH | -OH | -C15H12O5 | -OH | ||
| 3. | Apigenin | -OH | -OH | -OH | |||
| 4. | Baicalein | -OH | -OH | -OH | |||
| 5. | Chrysin | -OH | -OH | ||||
| 6. | Luteolin | -OH | -OH | -OH | -OH | ||
| 7. | Nobiletin | -OCH3 | -OCH3 | -OCH3 | -OCH3 | -OCH3 | |
| 8. | Orientin | -OH | -OH | -C6H11O5 | -OH | -OH | |
| 9. | Vitexin | -OH | -OH | -C6H11O5 | -OH |
Figure 37, 8-dihydroxyflavone.
Figure 4Amentoflavone.
Figure 5Apigenin.
Figure 6Baicalein.
Figure 7Chrysin.
Figure 8Luteolin.
Figure 9Nobiletin.
Figure 10Orientin.
Figure 11Vitexin.
Figure 12SAR of Flavones.
Figure 13Skeleton of Flavonols.
Flavonols and their structure activity relationship.
| Sr. No. | Flavonols | R | C5 | C6 | C7 | C8 | C3′ | C4′ | C5′ |
|---|---|---|---|---|---|---|---|---|---|
| 1. | 3,5,6,7,8,3′,4′-Heptamethoxyflavone | -CH3 | -OCH3 | -OCH3 | -OCH3 | -OCH3 | -OCH3 | -OCH3 | |
| 2. | Fisetin | H | OH | OH | OH | ||||
| 3. | Hyperoside | (C6H11O5) | -OH | -OH | -OH | -OH | |||
| 4. | Icariin | H | OH | -O(C6H11O5) | C5H9 | OCH3 | |||
| 5. | Isoquercitrin | -(C6H11O5) | OH | OH | OH | OH | |||
| 6. | Kaempferitrin | (C6H11O4) | -OH | -O(C6H11O4) | -OH | ||||
| 7. | Kaempferol | H | OH | OH | OH | ||||
| 8. | Kaempferol-3-O-β-D-glucose | -(C6H11O5) | OH | OH | OH | ||||
| 9. | Miquelianin | -(C6H9O6) | OH | OH | OH | OH | |||
| 10. | Myricetin | H | OH | OH | OH | OH | OH | ||
| 11. | Myricitrin | -(C6H11O4) | OH | OH | OH | OH | OH | ||
| 12. | Quercetin | H | OH | OH | OH | OH | |||
| 13. | Quercetin-3-O-β-D-glucose | -(C6H11O5) | OH | OH | OH | OH | |||
| 14. | Quercitrin | -(C6H11O4) | OH | OH | OH | OH | |||
| 15. | Rutin | -(C12H21O9) | OH | OH | OH | OH |
Figure 143,5,6,7,8,3′,4′-heptamethoxyflavone.
Figure 15Fisetin.
Figure 16Hyperoside.
Figure 17Icariin.
Figure 18Isoquercitrin.
Figure 19Miquelianin.
Figure 20Kaempferitrin.
Figure 21Kaempferol.
Figure 22Quercitrin.
Figure 23Quercetin-3-O-beta-D-glucoside.
Figure 24Kaempferol-3-O-beta-D-glucoside.
Figure 25Myricetin.
Figure 26Myricitrin.
Figure 27Quercetin.
Figure 28Rutin.
Figure 29SAR of Flavonols.
Figure 30Skeleton of Flavanones.
Flavanones and their structure activity relationship.
| Sr. No. | Flavanone | C5 | C7 | C3′ | C4′ |
|---|---|---|---|---|---|
| 1. | Hesperidin | -OH | -O(C12H21O9) | -OH | -OCH3 |
| 2. | Isosakuranetin-5- | -O(C12H21O9) | -OH | -OCH3 | |
| 3. | Liquiritin | -OH | -O(C6H11O5) | ||
| 4. | Naringenin | -OH | -OH | -OH | |
| 5. | Naringin | -OH | -O(C12H20O9) |
Figure 31Hesperidin.
Figure 32Isosakuranetin-5-O-rutinoside.
Figure 33Liquiritin.
Figure 34Isoliquiritin.
Figure 35Naringenin.
Figure 36Naringin.
Figure 37SAR of Flavanones.
Figure 38Skeleton of Flavanonols.
Flavanonols and their Structure activity relationship.
| Sr. No. | Flavanonols | R’ | C5 | C6 | C3′ | C4′ | C5′ |
|---|---|---|---|---|---|---|---|
| 1. | Astilbin | -O(C6H11O4) | -OH | -OH | -OH | -OH | |
| 2. | Dihydromyricetin | -H | -OH | -OH | -OH | -OH | -OH |
Figure 39Astilbin.
Figure 40Dihydromyricetin.
Figure 41Skeleton of Flavanols.
Figure 42Catechin.
Figure 43Epicatechin.
Figure 44Epigallocatechin gallate.
Figure 45Silibinin.
Figure 46Possible anti-depressant mechanisms of flavonoids. cAMP, cyclic adenosine monophosphate; MAP, mitogen-activated protein; mTOR, mammalian target of rapamycin; PKA, protein kinase A; ERK, extracellular regulated kinase; PKC, protein kinase C.
Figure 47Effect of flavonoids on brain neurotransmitters. P13K, phosphoinositide 3-kinases; Akt (PKB), protein kinase B; mTOR, mammalian target of rapamycin; PLCγ, phospholipase C gamma; PKC, protein kinase C; MEK, mitogen-activated protein kinase; ERK1/2, extracellular regulated kinase 1 and 2; CREB, cAMP-response element binding protein; BDNF, brain-derived neurotrophic factor.
Figure 48Inhibitory effect of flavonoids on lipid-peroxidation. PL, phospholipids; PKC, protein kinase C; DAG, diacylglycerol; PLA2, phospholipases A2; AA, arachidonic acid; COX, cyclooxygenase; LOX, lipoxygenases; IP3, inositol trisphosphate; ER, endoplasmic reticulum; ATP, adenosine triphosphate; NOS, nitric oxide synthase.
Figure 49Possible antioxidant mechanism of flavonoids. ROS, reactive oxygen species; RNS, reactive nitrogen species; P13K, phosphoinositide 3-kinases; PKC, protein kinase C; MAP, mitogen-activated protein; cNOS, cyclic reactive oxygen species; ERK, extracellular regulated kinase; Akt (PKB), protein kinase B; BDNF, brain-derived neurotrophic factor; CREB, cAMP-response element binding protein; mTOR, mammalian target of rapamycin; Arc/Arg 3,1, Activity-regulated cytoskeletal-associated protein.
Figure 50Production of nitric oxide, superoxide and peroxynitrite. NO, nitric oxide; R*, reactive free radicals.
Figure 51Inhibitory action of flavonoids on Xanthine oxidase pathway. NO, nitric oxide; NO3, nitrate; HNO3, nitric acid; O2, oxygen; O2*, oxidative free radical; H2O2, hydrogen peroxide; SOD, superoxide dismutase; GSH-PX, glutathione peroxidase; CAT, catalase; OH*, hydroxyl free radical; NO2*, nitrogen dioxide radical.
Figure 52Effect of flavonoids on BDNF/TrkB signalling pathway. BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin receptor kinase B; Ras, rapidly accelerated sarcoma; Raf, rapidly accelerated fibrosarcoma; MEK, mitogen-activated protein kinase; ERK, extracellular regulated kinase; RSK, ribosomal S6 kinase; P13K, phosphoinositide 3-kinases; PDK1, 3-phosphoinositide-dependent kinase 1; Akt(PKB), protein kinase B; PLCγ, phospholipase C gamma; IP3, inositol trisphosphate; CAMK, Ca2+/calmodulin-dependent protein kinase; DAG, diacylglycerol; PKC, protein kinase C; CREB, cAMP-response element binding protein.
Isolated flavonoids with anti-depressant action.
| Flavones | ||||||
|---|---|---|---|---|---|---|
| Isolated Bioactive Flavonoids | Doses | Route | Animal Species | Treatment Duration | Mechanism of Actions | References |
| 7,8-Dihydroxyflavone | 1, 3, and 10 mg/kg | Intra-gastric | Male Swiss mice | 60 min before |
Modulation of nitric oxide signalling pathway Increased BDNF level in prefrontal cortex and hippocampus | [ |
| 10 and 20 mg/kg | Intraperitoneal | Male C57BL/6 mice | 28 days |
Permeable to the BBB and mimics hippocampal brain-derived neurotrophic factor action Acted as TrkB receptor-specific agonist | [ | |
| 5 mg/kg | Oral | Male C57BL/6 mice | 21 days |
Permeable to the BBB and mimics hippocampal brain-derived neurotrophic factor action Acted as TrkB receptor-specific agonist | [ | |
| Amentoflavone | 6.25, 12.5, 25, or 50 mg/kg | Oral | Male Swiss albino mice | 3 days |
Interacted with serotonergic (especially, 5- HT2 receptors) and noradrenergic (especially, | [ |
| Apigenin | 12.5 and 25 mg/kg | I.p. | Male ddY mice | 1 h |
Regulated dopaminergic system | [ |
| 20 mg/kg | I.g. | Male Sprague–Dawley rats | 21 days |
Inhibited IL-1 production Inhibited NLRP3 inflammasome expression Up-regulated PPAR expression | [ | |
| 20 and 40mg/kg | Oral | Male ICR mice | 21 days |
Up-regulated BDNF concentrations in the hippocampus | [ | |
| 25, 50 mg/kg | I.p. | Male ICR mice | 7 days |
Inhibited nitric oxide synthase Inhibited cyclooxygenase-2 | [ | |
| Baicalein | 1, 2, or 4 mg/kg | I.p. | Male Kunming mice | 7 and 21 days |
Reversed in the reduction of extracellular ERKs phosphorylation Enhanced level of hippocampal BDNF expression | [ |
| 10, 20, and 40 mg/kg | I.p. | Male Sprague–Dawley rats | 14 days |
Prevented decrease of BDNF level and dopamine concentrations in hippocampus | [ | |
| 10, 20, or 40 mg/kg | Oral | Male Wistar rats | 35 days |
Decreased COX-2 activity and as well its expression Reduced of PGE2 levels in brain | [ | |
| Chrysin | 5 and 20 mg/kg | Oral | Female C57B/6J mice | 28 days |
Increased BDNF and nerve growth factor levels in cortex prefrontal and hippocampus Antioxidant activity | [ |
| 5 and 20 mg/kg | Oral | Male C57B/6J mice | 14 days |
Increased brain-derived neurotrophic factor synthesis Increased serotonin level in hippocampus | [ | |
| 5 and 20 mg/kg | Oral | Female C57B/6J mice | 28 days |
Reverse the decreases hippocampal 5-HT levels Reduction in IL-1β, TNF-α, IL-6 and kynurenine levels Increased the caspases activities in cerebral | [ | |
| Luteolin | 50 mg/kg | Oral | Male ICR | 23 days |
Suppressed hippocampal endoplasmic reticulum stress via inhibiting the expression of endoplasmic reticulum stress related proteins | [ |
| 5 or 10 mg/kg | Oral | Male ICR | 30 min before |
Potentiated the GABAA receptor- Cl− ion channel complex | [ | |
| Nobiletin | 20, 50, or 100 mg/kg | Oral | Male ICR mice | After 60 min |
Activated serotonergic, noradrenergic and dopaminergic systems | [ |
| Orientin | 20 and 40 mg/kg | Oral | Male Kunming mice | 21 days |
Increased BDNF level Increased in levels of serotonin, and nor-epinephrine levels in the hippocampus and prefrontal cortex Improved central oxidative stress, neuroplasticity and neurotransmission MAO inhibition | [ |
| Vitexin | 10,20 and 30 mg/kg | Oral | Male BALB/c mice | 60 min before test |
Increased monoamines level in synaptic cleft Interacted and modulated noradrenergic α2, dopaminergic D1, D2, D3 and serotonergic 5-HT1A receptors | [ |
|
| ||||||
| 3,5,6,7,8,3′,4′-Heptamethoxyflavone | 50 mg/kg | S.c. | C57BL/6 mice | 25 days |
Increased in hippocampal BDNF concentration Increased in neurogenesis and neuroplasticity in the hippocampus | [ |
| Fisetin | 10 or 20 mg/kg | Oral | Male ICR mice | 4 days |
Inhibited MAO activity Up-regulation of serotonin in and nor-epinephrine levels | [ |
| 20, 40, or 80 mg/kg | Oral | Male ICR mice | 7 days |
Antagonized nitrite levels and iNOS mRNA expression via modulating NF- Reversed LPS-induced overexpression of proinflammatory cytokine (especially, IL-6, IL-1β and TNF-α) | [ | |
| 5 mg/kg | Oral | Male ICR mice | 21 days |
Increased phosphorylation and activation of TrkB (pTrkB) in the hippocampus | [ | |
| Hyperoside | 2.5, 5, and 10 μg/mL | I.p. | PC12 | 4 h |
Cytoprotective action via increased in expression of BDNF and as well CREB by activating signalling pathway, i.e., AC–cAMP–CREB | [ |
| 10, 20, or 40 mg/kg | I.p. | Male CF1 mice | 14 days |
Activated dopaminergic system via D2-DA receptors | [ | |
| 0.6 mg/kg | Oral | Male CD rats | 14–56 days |
Modulated hypothalamic-pituitary-adrenal axis by reduction of plasma ACTH and corticosterone concentration | [ | |
| Icariin | 20 and 40 mg/kg | Oral | Male Sprague–Dawley rats | 35days |
Anti-oxidant action Inhibited activation of NF-κB signaling and also, NLRP3 -inflammasome/caspase-1/IL-1b axis Anti-inflammatory action | [ |
| 5 and 10 mg/kg | Oral | Male C57BL/6J mice | 28 days |
Increased BDNF expression Inhibited the increases in serum TNF-α and IL-6 level Restored the impairment of gluco-corticoid sensitivity | [ | |
| 20 and 40 mg/kg | Oral | Male Sprague–Dawley rats | 35 days |
Restored the negative feedback regulation of the HPA- axis Decreased the expression levels of FKBP5 and SGK1 | [ | |
| 60 mg/kg | Oral | Male Sprague–Dawley rats | 21 days |
Increased in hippocampal BDNF concentrations Reversed CORT-induced depression via regulating disturbed metabolic pathways | [ | |
| Isoquercitrin | 0.6 mg/kg | Oral | Male CD rats | 14–56 days |
Modulated hypothalamic-pituitary-adrenal axis by reducing plasma corticosterone and ACTH concentration | [ |
| 2.5 mg/kg | Oral | Male Sprague–Dawley rats | 14 days |
Protected from oxidative stress | [ | |
| Kaempferitrin | 1, 5, 10, or 20 mg/kg | Oral | Male Swiss Webster mice | 4 days |
Interacted with presynaptic 5-HT1A receptors and | [ |
| Kaempferol | 30 mg/kg/day | Oral | Male ICR mice | 14 days |
Increased expression of plasma β-endorphin levels or hypothalamic POMC mRNA | [ |
| 0.35 mM/kg | I.p. | Male Swiss mice | 60 min prior to the test |
Increased in NE, DA and 5-HT and also reduced 5-HT metabolism | [ | |
| Kaempferol-3-O-β-D-glucose | 0.35 mM/kg | I.p. | Male Swiss mice | 60 min prior to the test |
Increased in NE, DA and 5-HT and also reduced 5-HT metabolism | [ |
| Miquelianin | 0.6 mg/kg | Oral | Male CD rats | 14 days |
Modulated hypothalamic-pituitary-adrenal axis by reducing plasma ACTH and corticosterone concentration | [ |
| Myricetin | 50 mg/kg | I.p. | Male C57BL/6 mice | 21 days |
Increased BDNF concentrations in hippocampus Reduced oxidative stress | [ |
| Myricitrin | 10 mg/kg | I.p. | Male Balb/C mice | 21 days |
Facilitated hippocampal neurogenesis | [ |
| Quercetin | 2.5, 5, 10, 20 and 40 mg/kg | Oral | Male Sprague–Dawley rats | 14 days |
Protected from oxidative stress | [ |
| 0.35 mM/kg | I.p. | Male Swiss mice | 60 min prior to the test |
Increased in NE, DA and 5-HT and also reduced 5-HT metabolism | [ | |
| 50 or 100 mg/kg | I.p. | Male Wistar rats | 21 days |
Attenuated depressive-like behaviours | [ | |
| 40 and 80 mg/Kg | Oral | Male olfactory bulbectomy rats | 14 days |
Neuroprotective effects via microglial inhibitory pathway Suppressed oxidative-nitrosative stress mediated neuroinflammation-apoptotic cascade | [ | |
| 25 mg/kg | Oral | Female Swiss mice | 14 days |
Antagonised NMDA receptors Inhibited synthesis of nitric oxide | [ | |
| Quercetin- | 0.35 mM/kg | I.p. | Male Swiss mice | 60 min prior to the test |
Increased in NE, DA and 5-HT and also reduced 5-HT metabolism | [ |
| Quercitrin | 30 mg/kg/day | Oral | Male ICR mice | 14 days |
Increased expression of plasma β-endorphin levels and hypothalamic POMC mRNA | [ |
| Rutin | 0.3, 1, 3, 10 mg/kg | Oral | Male Swiss mice | 4 days |
Increased the concentration of serotonin and noradrenaline in the synaptic cleft | [ |
| 5 and 10 mg/kg | Oral | Male Sprague–Dawley rats | 14 days |
Protected from oxidative stress | [ | |
|
| ||||||
| Hesperidin | 25, 50, or 100 mg/kg | Oral | Male albino Wistar rats | 21 days |
Attenuated hyperglycaemia and restored brain monoamines level Increased the neurogenesis and brain-derived neurotrophic factor levels | [ |
| 0.01, 0.1, 0.3, and 1 mg/kg | I.p | Male Swiss mice | 21 days |
Interacted with the | [ | |
| 0.01, 0.1, 0.3, and 1 mg/kg | I.p. | Male Swiss mice | 21 days |
Interacted with the 5-HT1A receptors Antioxidant effect | [ | |
| 25 and 50 mg/kg | Oral | Male ICR mice | 21 days |
Increased ERK phosphorylation and BDNF expression in hippocampus | [ | |
| 0.01, 0.1, 0.3, and 1 mg/kg | I.p. | Male Swiss mice | 21 days |
Increased hippocampal brain-derived neurotrophic factor levels Inhibited l-arginine-NO-cGMP pathway Decreased hippocampal nitrate/nitrite (NOX) levels | [ | |
| 0.4, 4, 8, 16, and 32 mg/kg | Oral | Male imprinting control region mice | After 1 h |
Increased neuronal level of the 5-HT and dopamine | [ | |
| 50 mg/kg | Oral | Male C57BL/6 mice | 13 days |
Increased in hippocampal BDNF and nerve growth factor concentrations Modulation of pro-inflammatory cytokine Maintained brain plasticity Inhibition of acetylcholinesterase activity | [ | |
| Isosakuranetin-5- | 15 and 30 mg/kg | Oral | Male ICR mice | 24, 18, and 1 h before test |
Significantly inhibited depression-like behaviours | [ |
| Liquiritin | 10, 20 and 40 mg/kg | G.i. | Male mice | 30 min before |
Increased in 5-HT and NE levels in hippocampus, hypothalamus and cortex | [ |
| Isoliquiritin | 10, 20 and 40 mg/kg | G.i. | Male mice | 30 min before |
Increased 5-HT and NE levels in hippocampus, hypothalamus and cortex | [ |
| Naringenin | 5, 10 and 20 mg/kg | Oral | Male ICR mice | 14 days |
Increased serotonin, dopamine, norepinephrine and glucocorticoid receptor levels in the brain hippocampus | [ |
| 20 mg/kg | Oral | Male ICR mice | 21 days |
Activation of hippocampal BDNF signalling pathway | [ | |
| Naringin | 50 and 100 mg/kg | I.p. | Male Wistar rats | 14 days |
Significantly inhibited DOX-induced raise in plasma corticosterone, TNF-α and IL-1β levels in hippocampus Modulated of 5-HT1A and kappa-opioid receptors | [ |
|
| ||||||
| Astilbin | 10, 20, or 40 mg/kg | I.p. | Male C57BL/6J mice | 21 days |
Upregulated mono-aminergic neurotransmitters Activated of BDNF signalling pathway Inhibition of MAO activity | [ |
| Dihydromyricetin | 10 and 20 mg/kg | I.p. | Male C57BL/6J mice | 7 days |
Increased mRNA expression for BDNF in the hippocampus Inhibited neuro-inflammation | [ |
|
| ||||||
| Catechin | 88.6 and 58.9 µM | - | Wistar male rat | - |
Inhibition of MAO activity | [ |
| Epicatechin | 88.6 and 58.9 µM | - | Wistar male rat | - |
Inhibition of MAO activity | [ |
| Epigallocatechin gallate | 500 ng/mL | - | Sprague–Dawley rat brains | 24 h |
Reduced neuroinflammation | [ |
|
| ||||||
| Silibinin | 100 and 200 mg/kg | Oral | Either sex Wistar rats | 14 days |
Altered immunological, endocrine and monoamines systems such as 5-HT, DA, NE, MDA formation, TNF-α, IL-6 and BDNF levels in hippocampus and cerebral cortex. | [ |
Figure 53SAR of Flavonoids.